Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit - Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024...

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...